menu
    • menu
    [{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Aqualung Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"ALT-100","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institute of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institute of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Azithromycin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"UCLA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"CAR-T therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institution of Health","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ National Institution of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Crestone","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"CRS0540","moa":"PolC","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"REGN10933","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Entasis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"ETX0462","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"ProLynx","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"PTH(1-34)","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institute of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institute of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"National Institutes of Health","amount2":6.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":6.5,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ Ntional Institute of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ Ntional Institute of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Plakous Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Protego-PD","moa":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ National Institute of Health","highestDevelopmentStatusID":"5","companyTruncated":"National Institutes of Health \/ National Institute of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Plex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"CAP4196","moa":"Alpha A crystallin","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"National Institutes of Health \/ National Institute of Health","highestDevelopmentStatusID":"5","companyTruncated":"National Institutes of Health \/ National Institute of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Lamassu Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"RABI-767","moa":"Lipase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Vivasc Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"CTP-Amio","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Antiviral monoclonal antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ National Institute of Health","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ National Institute of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Cancer Targeted Technology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"CTT1403","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institute of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institute of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Moderna","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Moderna"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"Sapphire Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"SPX-1009","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"The Division of Cancer Treatment and Diagnosis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Chrysalis BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Rusalatide Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Galidesivir","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ National Institute of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institute of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Gene therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institute of Health","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ National Institute of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Intravacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Inactivated EV D68 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Heparin Sodium","moa":"Antithrombin III","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ National Institute of Health","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ National Institute of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"INmune Bio","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"XPro1595","moa":"TNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institute of Health","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ National Institute of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"CEL-SCI","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"CEL-4000","moa":"Il-17 alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institute of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institute of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Jupiter Orphan Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Convalescent plasma","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Opioid vaccines","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"National Institutes of Health","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institute of Health","highestDevelopmentStatusID":"7","companyTruncated":"National Institutes of Health \/ National Institute of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Hyperimmune immunoglobulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Knopp Biosciences LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Kv7.2\/Kv7.3 cellular potassium channel","graph1":"Neurology","graph2":"Discovery","graph3":"National Institutes of Health","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Humanigen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Humanigen"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"Zenith Epigenetics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Ipilimumab","moa":"BET","graph1":"Oncology","graph2":"Undisclosed","graph3":"The Division of Cancer Treatment and Diagnosis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 Human Immune Globulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Meabco","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"BP-C2","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Connectyx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody-drug conjugate","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Connectyx","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ Connectyx"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"131-I Apamistamab","moa":"CD45","graph1":"Oncology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Surrozen","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"GEO-CM01","moa":"Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ GeoVax","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ GeoVax"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"tablet","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Ocuphire Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Vamorolone","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Bria-OTS","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ BriaCell","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ BriaCell"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Coda Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"AAV Vector based gene therapy","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"SteroTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Fluasterone","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Plus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Athira Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"ATH-1017","moa":"HGF","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Pre-filled syringe","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Alume Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"ALM-488","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ National Institute of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ National Institute of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Soligenix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"CiVax","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Brii Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"BRII-196","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Eli Lilly"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"CohBar","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"CB5064 Analogs","moa":"Apelin receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"IRISYS, LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Drinabant","moa":"CB1","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BRII-196","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Institutes of Health \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Eli Lilly"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"CAR-T cell therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Heparin Sodium","moa":"Antithrombin III","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"OncoSec Immunotherapies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"SARS-CoV-2 spike protein plasmid DNA vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institute Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institute Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"EVT894","moa":"Chikungunya viral protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"National Institutes of Health \/ National Institute Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institute Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"CYT-503","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Avexegen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Funding","leadProduct":"Neuregulin-4-based therapy","moa":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sodium Hyaluronate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Oragenics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"CoV-2 S-2P","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Institutes of Health \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ Eli Lilly"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Propella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Abiraterone decanoate","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Cancer Institute \/ Propella Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Propella Therapeutics"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Cybrexa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Alphalex-exatecan","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Cybrexa Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ Cybrexa Therapeutics"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"NICHD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ NICHD","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ NICHD"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Aridis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"AR-711","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"REGN3048","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"NU-0129","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Medicago","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"AS03","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Precigen","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"PRGN-2012","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"ImmunogenX","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Hyperimmune immunoglobulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Hyperimmune immunoglobulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273.351","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Moderna","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ Moderna"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IC14","moa":"CD14","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"ONK Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"ONKT101","moa":"CCR7 receptor","graph1":"Oncology","graph2":"Discovery","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ ONK Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"National Institutes of Health \/ ONK Therapeutics"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Enzychem Lifesciences Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"SOUTH KOREA","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"EC-18","moa":"","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Shasqi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"SQL70","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Versiti","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Heparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Human Polyclonal Antibody Therapeutic","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Dalbavancin","moa":"D-Ala-D-Ala moiety of NAM\/NAG peptide subunits of peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Cartesian Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"RNA Engineered Allogeneic Human Mesenchymal Stem Cells","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Cassava Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"SiteOne Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Enanta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"EDP-514","moa":"HBV core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Trevena","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"TRV027","moa":"AT1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Constant Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Angiotensin-(1-7)","moa":"ARAS pathway","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Spero Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Funding","leadProduct":"SPR206","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"ST101","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ Sapience Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ Sapience Therapeutics"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"TGF beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institutes of Health \/ National Institute for Health Research","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ National Institute for Health Research"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"VRC-FLUMOS0111-00-VP","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"PF614","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Pelcitoclax","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ Ascentage Pharma"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Q-State Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Funding","leadProduct":"Antisense Oligonucleotide Therapeutics","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"2","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Praxis Bioresearch","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"PRX-P4-003","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Strand Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Funding","leadProduct":"mRNA-based Therapeutics","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"TransCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Funding","leadProduct":"TTX-MC138","moa":"microRNA-10b","graph1":"Oncology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Advanced Chemotherapy Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Humanigen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Humanigen","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ Humanigen"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Cellectar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Iopofosine I-131","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"TumorGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"The Division of Cancer Treatment and Diagnosis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute","highestDevelopmentStatusID":"3","companyTruncated":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"COVID-19 Human Immune Globulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Mnk1\/2 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Cancer Institute \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ NIH"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Senti Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"AnaBios","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"ANB-504","moa":"Dual sodium channels","graph1":"Neurology","graph2":"IND Enabling","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"5","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"1910 Genetics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"2","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Funding","leadProduct":"ST316","moa":"Beta catenin","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"N-803","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"9","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Appello Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"AP-472","moa":"Metabotropic glutamate receptor type 4","graph1":"Neurology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Enesi Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Recombinant Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Societal CDMO","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Funding","leadProduct":"Enkephalin","moa":"MAO transporter","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Immuno Globulin","moa":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Mustang Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Funding","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"PDS Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Versamune-TARP","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Athenex","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Allogeneic NKT Cell Therapy","moa":"Mutated p53","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Strand Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"mRNA-based CAR-T Immunotherapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"4E Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"4ET1103","moa":"MNK receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"National Institutes of Health","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Enkephalin","moa":"Delta opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"4E Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"4ET1103","moa":"MNK receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Delpor","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Tizanidine HCl","moa":"Adrenergic receptor alpha-2","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"CF33-hNIS-antiPDL1","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Delix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"DLX-7","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"I27-Breg","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"National Eye Institute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"National Eye Institute \/ Not Applicable"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Irofulven","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ION363","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CD22-directed CAR T cell Therapy","moa":"CD22","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Synairgen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"National Institutes of Health \/ National Institute of Health","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ National Institute of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Privo Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","graph1":"Immunology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"BG505 MD39.3 mRNA","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Human Polyclonal Antibody Therapeutic","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Chimeron Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV2 antigen","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"AV-1959D","moa":"Amyloid beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institute on Aging","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"SQZ Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"Allogeneic Cell Replacement Therapy","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"BioCorRx","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Synaptogenix","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Kintara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Copernicus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"DNA Nanoparticle-based Gene Therapy","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"Neuronascent","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NNI-362","moa":"Allosteric p70S6 kinase","graph1":"Neurology","graph2":"Phase I","graph3":"National Institute on Aging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Bria-OTS","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Ankyra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"ANK-101","moa":"Cytokines","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Cocrystal Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"CDI-988","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Synaptogenix","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"NextCure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"NC525","moa":"LAIR-1","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Portage Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"STI-001","moa":"STING","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"ILiAD Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Tuberculosis Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"BioCorRx","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"National Institutes of Health \/ National Institutes Of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institutes Of Health"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Osivax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"PostEra","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Antiviral Therapeutic","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"National Institutes of Health","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Pill","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"3","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Antiviral Therapeutic","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"3","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioCorRx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Naltrexone","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Altesa Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Antiviral Therapeutic","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"National Institutes of Health","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"2","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Antiviral Therapeutic","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"National Institutes of Health","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"DNA-based Vaccine","moa":"Amyloid beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institute on Aging","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Beta-amyloid Vaccine","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institute on Aging","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Kintara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"TransCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Achieve Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Cocrystal Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"CDI-873","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"scAAV2-P1ND4v2","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"AVM Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Kovina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"HPV protein","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioCorRx","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GM-CSF","graph1":"Immunology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Benfotiamine","moa":"Transketolase","graph1":"Neurology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Zenith Epigenetics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ZEN003694","moa":"BET","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"QSAM Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Samarium-153 DOTMP","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"PDS Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"PDS0202","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Creative Bio-Peptides","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"RAP-103","moa":"CXCR4","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Oryzon Genomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Crizotinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"12","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"GreenLight Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"mRNA-Based COVID-19 Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioXcel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Film","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"7 Hills Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"7HP349","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"STAT3 protein","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Cancer Institute","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"TNX-1300","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"Oligomerix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"OLX-07010","moa":"Tau protein","graph1":"Neurology","graph2":"IND Enabling","graph3":"National Institute on Aging","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Helocyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"CMV-modified Vaccinia Ankara Vaccine","moa":"pp65 protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"AUM LifeTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"Antisense Oligonucleotides","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"South Rampart Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diethylamide","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Evaxion Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Multivalent Gonorrhea Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Kovina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"HPV protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAV-based NPHP5 Gene Thearapy","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"PDS Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"2-deoxy-D-glucose Prodrug","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Cognition Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"CT1812","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"AN2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"9","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Maxwell Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Antimicrobial Peptides","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"ST101","moa":"C\/EBP beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Intravacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Recombinant Human IL-12","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Phoenix Pharmalabs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"PPL-138","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Synergys Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"SYN-001","moa":"Vasculogenic Mimicry","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"WRAIR_EPa11","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Enalare Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ENA-001","moa":"Potassium ion channel","graph1":"Sleep","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Mustang Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"MB-106","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"ProLynx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Omniose","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Bioconjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"ARTEMIS T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"Trethera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Eye Institute \/ National Eye Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"F3-8-60","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Modifi Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"MGMT","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"HEPLISAV-B","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Dynavax Technologies","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Dynavax Technologies"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Aptinyx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"NYX-783","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"RSVpreF","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Navrogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"NAV-001","moa":"Mesothelin","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Cancer Institute \/ Navrogen","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Navrogen"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Kyverna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Nephrology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"MediPharm Labs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Liquid","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"PharmaJet","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"HPV Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institutes of Health \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ NIH"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Turnstone Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Oncolytic Viral Immunotherapy","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Scynexis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"SCY-247","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Efineptakin Alfa","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"TeraImmune","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"TI-168","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"5","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Lorazepam","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"National Institutes of Health","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Sensei Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Lintuzumab-ac225","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Gritstone bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Aprea Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"ATRN-119","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"Praetego","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"PTG-630","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Eye Institute \/ National Eye Institute"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Stalicla","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Mavoglurant","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Tessa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"TT11X","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"T-cell based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ Eureka Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ Eureka Therapeutics"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Disc medicine","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Bitopertin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"T cell-based Therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"TransCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Omeros","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"OMS527","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Nogapendekin alfa Inbakicept","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Funding","leadProduct":"ST316","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Iterion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tegavivint","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"H1ssF-3928 mRNA-LNP","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Not Applicable"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"SiteOne Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"STC-004","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Trethera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Helocyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"CMV-MVA Triplex Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Trethera","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Kintara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"REM-001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"Cognition Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"National Institute on Aging","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"TFF Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Universal Influenza Virus Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Marker Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Zedenoleucel","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Pluri","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"PLX-R18","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Caeregen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"CTR-107","moa":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Advent","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Vitamin A Palmitate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Access to Advanced Health Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Chikungunya Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Sparian Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"SBS-518","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institutes of Health","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Trethera","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Bria-OTS","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Exavir Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"XVIR-110","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"5","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Imunon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"DNA-based Lassa Virus Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Cebranopadol","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institute on Drug Abuse","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"BITT","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"BITT-101","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"ResVita Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"RVB-101","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Sarcomatrix","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"S-969","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Omniose","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"GBS Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"2","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"GigaGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"GIGA-564","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Aligos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"ALG-097558","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"Neurodon","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"National Institute on Aging","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Apamistamab-I-131","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Ocugen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"OCU500","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Cessation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"CSX-1004","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Traverse Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"RevBio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"TN-ADBS","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"iVeena","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"IVMED-85","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Eye Institute \/ National Eye Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"L2P Research","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Orlance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Camino Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Bio-identical Progesterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Ring","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Delix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"DLX-007","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Syena","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SY-101","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Syena","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ Syena"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Capricor Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Exosome-based Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Blacksmith Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"FG-2101","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Gilgamesh Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Ibogaine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Lamassu Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"SA53","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"ReAlta Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"RLS-0071","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Camino Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"SBP-9330","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Osivax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"OVX836","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioCorRx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Naltrexone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Pellet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"BlueSphere Bio","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"TCR T-cell Therapy","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"2","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Precigen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"PRGN-2012","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ensitrelvir Fumaric Acid","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"12","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"RocketVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"RVX-sCPD9","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"KBio","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"EV68-228-N","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Pluri","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Avoplacel","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Anebulo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Selonabant","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Versatope Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Marker Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Neldaleucel","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"CNDR-51997","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Institute on Aging","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"12","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Evoq Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"TransCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Biosplice","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Cirtuvivint","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"12","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"Foralumab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Orlance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"MACH-1-based Vaccine","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Allyx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"ALX-001","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"RevOpsis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"DENMARK","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"RO-104","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"12","companyTruncated":"National Eye Institute \/ National Eye Institute"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"EpiVario","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"12","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"EydisBio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Vaxxas","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"RSV Vaccine","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Vaxxas","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ Vaxxas"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Repare Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Camonsertib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"12","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Sparian Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"SBS-226","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Institutes of Health \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ National Institutes of Health"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Cancer Targeted Technology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"CTT2274","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"12","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Chrysalis BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Rusalatide Acetate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"12","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"GlycoMimetics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","graph1":"Technology","graph2":"Approved","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"12","companyTruncated":"National Cancer Institute \/ National Cancer Institute"}]

    Find Clinical Drug Pipeline Developments & Deals by National Institutes of Health

    Menu

    National Institutes of Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            National Cancer Institute

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            National Cancer Institute

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Uproleselan,Mitoxantrone,Etoposide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : GlycoMimetics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GlycoMimetics Phase 2/3 Uproleselan Study Fails To Meet Primary Cancer Endpoint

                            Details : GMI-1271 (uproleselan) is a E-selectin inhibitor, which is being evaluated to treat adults with newly diagnosed acute myeloid leukemia (AML) who are 60 years or older.

                            Brand Name : GMI-1271

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 29, 2024

                            Lead Product(s) : Uproleselan,Mitoxantrone,Etoposide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : GlycoMimetics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            National Institutes of Health

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            National Institutes of Health

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : EydisBio

                            Deal Size : $0.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            EydisBio Wins $0.5M Grant for Alzheimer’s TAK1 Inhibitor Program

                            Details : The grant will support EydisBio's pioneering research into new therapeutic approaches for Alzheimer's disease, focusing on the inhibition of TGFβ-activated protein kinase 1 (TAK1).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 23, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : EydisBio

                            Deal Size : $0.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            National Institutes of Health

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            National Institutes of Health

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALX-001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Allyx Therapeutics

                            Deal Size : $3.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Allyx Therapeutics Receives $3.3M NIH Grant for ALX-001 Clinical Studies

                            Details : The funding will support Allyx’s ALX-001, a highly-selective, first-in-class, synapse-targeted, disease-modifying oral therapy in development for Alzheimer’s disease and Parkinson’s disease.

                            Brand Name : BMS-9894923

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 15, 2024

                            Lead Product(s) : ALX-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Allyx Therapeutics

                            Deal Size : $3.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            National Eye Institute

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            National Eye Institute

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Recipient : RevOpsis Therapeutics

                            Deal Size : $1.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            RevOpsis Wins $1.8M Grant for Ophthalmic Therapy R&D Advancement

                            Details : The SBIR grant will fund critical R&D activities, including multidose GMP toxicology studies in nonhuman primates for RO-104, a first-in-class fully human modular tri-specific biologic.

                            Brand Name : RO-104

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 15, 2024

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Recipient : RevOpsis Therapeutics

                            Deal Size : $1.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            National Institutes of Health

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            National Institutes of Health

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MACH-1-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Orlance

                            Deal Size : $3.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Orlance Awarded $3.3M NIH Grant for MACH-1™ Enhanced Influenza Vaccine

                            Details : The proceeds will enable Orlance to leverage its innovative MACH-1 powdered vaccine and immunotherapy platform to address both seasonally-changing and highly-conserved influenza immunogens.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 10, 2024

                            Lead Product(s) : MACH-1-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Orlance

                            Deal Size : $3.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            National Institute on Drug Abuse

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            National Institute on Drug Abuse

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : EpiVario

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            EpiVario Awarded SBIR Grant from NIH to Develop Treatments for Opioid Use Disorder

                            Details : The grant will be used to advance the company's research towards developing a novel epigenetic regulator as a treatment for opioid use disorder (OUD).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 01, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : EpiVario

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            National Institutes of Health

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            National Institutes of Health

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Foralumab

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : Tiziana Life Sciences

                            Deal Size : $4.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Tiziana Receives $4M NIH Grant To Study Anti-CD3 in Alzheimer’s Disease

                            Details : The significant grant will fund a key research study over the next several years, advancing clinical studies of TZLS-401 (foralumab), anti-CD3 as a potential treatment for Alzheimer’s disease.

                            Brand Name : TZLS-401

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 19, 2024

                            Lead Product(s) : Foralumab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : Tiziana Life Sciences

                            Deal Size : $4.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            National Cancer Institute

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            National Cancer Institute

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Biosplice

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Biosplice Begins AML and MDS Trials Sponsored By National Cancer Institute

                            Details : The collaboration aims for Biosplice to expand its clinical candidate, SM08502 (cirtuvivint), as a standalone treatment and combination therapy in patients with AML and MDS.

                            Brand Name : SM08502

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 12, 2024

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Biosplice

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            National Institutes of Health

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            National Institutes of Health

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTX-MC138

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : TransCode Therapeutics

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            TransCode Wins $2M NIH Grant For Lead Candidate's Clinical Evaluation

                            Details : The proceeds will be used to support clinical development of TTX-MC138, a first-in-class therapeutic candidate, for the treatment of advanced solid tumors.

                            Brand Name : TTX-MC138

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 05, 2024

                            Lead Product(s) : TTX-MC138

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : TransCode Therapeutics

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            National Institutes of Health

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            National Institutes of Health

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Recipient : Evoq Therapeutics

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            EVOQ Therapeutics Secures $2 Million NIH Grant

                            Details : The Company intends to use the proceeds to accelerate the development of its platform and advance novel therapies for autoimmune diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 29, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Recipient : Evoq Therapeutics

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth